AUG 01, 2013
Cataract/Anterior Segment, Comprehensive Ophthalmology, Cornea/External Disease, Glaucoma, Neuro-Ophthalmology/Orbit, Ocular Pathology/Oncology, Oculoplastics/Orbit, Pediatric Ophth/Strabismus, Refractive Mgmt/Intervention, Retina/Vitreous, Uveitis
Merck & Co, Inc., reported worldwide sales of $11.0 billion for the second quarter of 2013, a drop of 11 percent compared with the quarter a year earlier. The company said the decline in sales was due to patents expiring and a negative impact of foreign exchange rates.
The company’s main ophthalmic products, Cosopt (dorzolamide hydrochloride-timolol maleate ophthalmic solution) and Trusopt (dorzolamide hydrochloride sterile ophthalmic solution 2%), had sales of $103 million in the second quarter of this year, a decrease of two percent from the same quarter last year.
Merck is forecasting full-year 2013 sales to be approximately five to six percent lower than last year’s sales at current exchange rates, with foreign exchange accounting for approximately three percentage points of the decline.